Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
09/2012
09/27/2012WO2012128082A1 Anti-mouse aggrus monoclonal antibody
09/27/2012WO2012127379A2 A method for the analysis of the evolution of gene sequences and the forecast of an emerging viral strain
09/27/2012WO2012127352A2 Mia (melanoma inhibitory activity) inhibitors for detecting, preventing and curing vitiligo
09/27/2012WO2012127289A1 R2r1/2 in diagnosis and therapy
09/27/2012WO2012127248A1 Method for the production of protein complexes and vaccine compositions comprising the same
09/27/2012WO2012127041A1 Method of screening antiretroviral compounds and vaccine
09/27/2012WO2012126879A1 Novel oprf/i fusion proteins, their preparation and use
09/27/2012WO2012126172A1 Peptides inhibiting adhesion of aspergillus fumigatus to cornea
09/27/2012WO2012126149A1 Mycobacterium tuberculosis fusion protein and its preparation method and use thereof
09/27/2012WO2012126118A1 Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
09/27/2012WO2012094300A3 Methods of treating age-related macular degeneration
09/27/2012WO2012068540A3 Neutralizing anti-ccl20 antibodies
09/27/2012WO2012064816A3 Methods of neutralizing viral infection
09/27/2012WO2012059598A3 Methods of treating rheumatoid arthritis using il-17 antagonists
09/27/2012WO2011098778A8 Peptides for vaccines against birch allergy
09/27/2012US20120244224 NANOSTRUCTURAL MATERIALS THAT INCREASE MINERALIZATION IN BONE CELLS AND AFFECT GENE EXPRESSION THROUGH miRNA REGULATION AND APPLICATIONS OF SAME
09/27/2012US20120244222 Osmotic mediated release synthetic nanocarriers
09/27/2012US20120244191 Compositions and methods for controlling diseases in animals
09/27/2012US20120244190 Vaccination of Sex Reversed Hybrid Tilapia (Oreochromis niloticus X O. aureus) With an Inactivated Vibrio vulnificus Vaccine
09/27/2012US20120244189 Treatment of infections
09/27/2012US20120244188 Treatment of Sensory Disturbance Disorders
09/27/2012US20120244187 Adenovirus Infection In Animals
09/27/2012US20120244186 Epinecidin-1 as a vaccine adjuvant for enhancing immune responses
09/27/2012US20120244184 Modified peptide vaccine derived from influenza m2
09/27/2012US20120244183 Influenza viruses and uses thereof
09/27/2012US20120244182 Use of tryptanthrin compounds for immune potentiation
09/27/2012US20120244181 Creating bioengineered lymph nodes
09/27/2012US20120244180 Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
09/27/2012US20120244178 Plasmodium falciparum antigens
09/27/2012US20120244176 Protein having immunogenicity of cedar pollen, polynucleotide encoding the protein, and use thereof
09/27/2012US20120244175 Tumor specific animal proteins
09/27/2012US20120244174 Treatment of tauopathies
09/27/2012US20120244173 Compositions and Methods for Enhancing Antigen-Specific Immune Responses
09/27/2012US20120244172 Conjudates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents
09/27/2012US20120244171 Cytotoxic benzodiazepine derivatives
09/27/2012US20120244170 Treating cancer by modulating mex-3
09/27/2012US20120244169 Treatment for Radiation-Induced Disorders
09/27/2012US20120244168 Human antibodies that bind human il-12 and methods for producing
09/27/2012US20120244167 Antibodies to m-csf
09/27/2012US20120244166 Neutralizing antibodies to hiv-1 and their use
09/27/2012US20120244165 Methods of treating amyloidosis comprising the use of anti-amyloid beta antibodies
09/27/2012US20120244164 Biological materials related to c-met
09/27/2012US20120244163 Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
09/27/2012US20120244162 Cross-species-specific bispecific binders
09/27/2012US20120244161 DOSAGE REGIMEN FOR ADMINISTERING AN EpCAMxCD3 BISPECIFIC ANTIBODY
09/27/2012US20120244160 Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
09/27/2012US20120244159 Specific Antibodies To Amyloid Beta Peptide, Pharmaceutical Compositions And Methods Of Use Thereof
09/27/2012US20120244158 Stable formulations of polypeptides and uses thereof
09/27/2012US20120244157 Use of tnf-alpha inhibitors for treating a nerve disorder mediated by nucleus pulposus
09/27/2012US20120244156 Leptin as an anti- amyloidogenic biologic and methods for delaying the onset and reducing alzheimer's disease-like pathology
09/27/2012US20120244155 Dendritic Cells (DCs) Targeting for Tuberculosis (TB) Vaccine
09/27/2012US20120244154 Activatable Binding Polypeptides and Methods of Identification and Use Thereof
09/27/2012US20120244153 Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
09/27/2012US20120244152 Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
09/27/2012US20120244151 Treatment of Cancer Involving Mutated KRAS or BRAF Genes
09/27/2012US20120244150 Anti-veev humanized antibody
09/27/2012US20120244149 Benzoxazepin pi3k inhibitor compounds and methods of use
09/27/2012US20120244148 Anti-interferon-alpha antibodies
09/27/2012US20120244147 Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
09/27/2012US20120244146 Treatment of tauopathies
09/27/2012US20120244145 Enhanced immunological responses
09/27/2012US20120244144 Pertussis antibodies and uses thereof
09/27/2012US20120244143 Drawn silk egel fibers and methods of making same
09/27/2012US20120244142 Antibody capable of recognizing hla class i
09/27/2012US20120244141 Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
09/27/2012US20120244121 Modulators of toll-like receptor 7
09/27/2012US20120244116 Method of treatment of philadelphia chromosome positive leukaemia
09/27/2012US20120244114 Antigen associated with rheumatoid arthritis
09/27/2012US20120244113 Immunogenic composition and methods
09/27/2012US20120244110 Fused tricyclic dual inhibitors of cdk 4/6 and flt3
09/27/2012US20120244077 Methods and compositions for maintenance of a functional wound
09/27/2012US20120244076 csPCNA Isoform Antibodies And Uses Thereof
09/27/2012US20120244069 Human monoclonal antibodies against cd25
09/27/2012CA2836007A1 Mouse anti-aggrus monoclonal antibodies
09/27/2012CA2830987A1 Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
09/27/2012CA2830908A1 Methods and compositions for improving antiangiogenic therapy with anti-integrins
09/27/2012CA2830901A1 Immunogenic compositions in particulate form and methods for producing the same
09/27/2012CA2830879A1 A novel process for preparation of polysaccharides
09/27/2012CA2830772A1 Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
09/27/2012CA2830628A1 Composition for treatment and diagnosis of pancreatic cancer
09/27/2012CA2830296A1 Method of screening antiretroviral compounds and vaccine
09/27/2012CA2829916A1 Rapid and prolonged immunologic-therapeutic
09/27/2012CA2829678A1 Method for the production of protein complexes and vaccine compositions comprising the same
09/27/2012CA2826490A1 R2r1/2 in diagnosis and therapy
09/26/2012EP2502999A2 Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
09/26/2012EP2502998A2 Recombinant toxin A/ToxinB vaccine against clostridium difficile
09/26/2012EP2502996A2 Anti-FGF23 antibody and pharmaceutical composition comprising the same
09/26/2012EP2502995A1 Pharmaceutical composition
09/26/2012EP2502938A2 Antibodies and immunoconjugates and uses therefor
09/26/2012EP2502937A2 Anti-CD 79b Antibodies And Immunoconjugates And Methods Of Use
09/26/2012EP2502936A1 Highly-functional mutant of humanized anti-egfr antibody variable region
09/26/2012EP2502935A2 Improved antibodies having altered effector function and methods for making the same
09/26/2012EP2502634A1 Herpes simplex virus combined subunit vaccines and methods of use thereof
09/26/2012EP2502628A2 Polynucleotides and polypeptide sequences involved in cancer
09/26/2012EP2502076A2 Methods for detecting a mycobacterium tuberculosis infection
09/26/2012EP2501723A1 Hepatitis b virus specific antibody and uses thereof
09/26/2012EP2501722A1 Method for producing t cell receptor-like monoclonal antibodies and uses thereof
09/26/2012EP2501717A1 Enhanced malaria msp-1 subunit vaccine
09/26/2012EP2501409A2 Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)
09/26/2012EP2501408A1 Formulations of antibody
1 ... 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 ... 1823